← Atlas Theme · spans 1 topics
National priority voucher programs compress regulatory reviews of breakthrough drugs from months to weeks.
A new regulatory pathway designed to address critical national health targets and domestic supply chains allows select life-saving therapies to secure FDA approval in under two months.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months The CNPV program is the voucher mechanism operationalizing weeks-long review of therapies deemed national priorities.
Science & Health
Revolution Medicines' Rasonque (Daraxonrasib) Wins Historic FDA Approval for Pancreatic Cancer Rasonque's FDA approval was dramatically accelerated months ahead of its PDUFA deadline through the CNPV program.